The FDA's Complete Response Letter (CRL) for Orviglance (NDA 220544) is now publicly accessible in redacted form through the FDA's openFDA transparency database. The letter's specifics raise the odds of a more demanding path to approval than previously indicated.

The clinical/statistical section of the published letter states the following, in summary:

The pivotal Phase 3 study (ASC-Man-P016, "SPARKLE") did not meet its pre-specified success criteria in its original reading: of the three initial independent readers, only one demonstrated statistical superiority of combined pre- and post-contrast imaging over pre-contrast imaging alone, across both co-primary endpoints (lesion contrast and lesion border delineation). A subsequent re-evaluation of the SPARKLE images was conducted using new readers. The FDA states that this re-evaluation was not adequately justified in the submission, and notes a possible risk of bias in the new readers' training given their exposure to the original images and initial read results. The FDA also states that the re-evaluation scored lesions using only T1-weighted images, which in the agency's assessment does not allow a demonstration of added clinical value over standard non-T1-weighted MRI sequences already used in this population. Based on these points, the FDA states that substantial evidence of effectiveness has not been demonstrated, and recommends that Ascelia conduct a new adequate and well-controlled study with revised reader training procedures and lesion scoring across the complete set of image sequences.

The letter's product quality section is fully redacted in the public version. The letter also references FDA's prior correspondence on the proposed proprietary name and standard requirements for any future resubmission, including a safety data update and a one-year window under 21 CFR 314.110 to resubmit or otherwise respond.

Ascelia's own July 12 update described its clinical position with respect to SPARKLE and the image re-read process, and stated that its approach had previously been discussed with the FDA ahead of submission. The company has stated it will provide a further update following the planned Type A meeting and receipt of the official meeting minutes.

The Type A meeting is now the key near-term catalyst. Ascelia has said it will submit a briefing package and request an expedited meeting, which, once granted, is typically convened within 30 days. From here, we see a range of possible outcomes, spanning from a fast resolution to a much longer path:

At the faster end, the FDA's remaining concerns could be addressed through clarification alone, for example around documentation or scope, without requiring new analysis of the imaging data itself. A step up from that would be a further re-evaluation of the SPARKLE images, this time scoring the complete set of acquired sequences rather than T1-weighted images only, which is the specific limitation the FDA flagged in its letter. If Ascelia can demonstrate that this revised approach was developed in close, documented alignment with the FDA, that could support a comparatively expedited route back toward approval, plausibly landing in late 2027 or early 2028.

At the far end of the range sits the scenario the FDA's letter explicitly recommends: an entirely new adequate and well-controlled clinical trial with fresh patient data. This would push a realistic approval timeline out to around 2029-2030 and would require financing well beyond Ascelia's current cash runway into 2027.

Historically, the FDA has applied a stringent standard when assessing whether a CRL response adequately resolves the deficiencies cited, and the agency's own letter here is unusually explicit in recommending a new study rather than a data reanalysis. That the FDA's letter names the new-study path directly, rather than leaving it as one interpretation among several, is itself a signal that this scenario carries more weight than management's public confidence would suggest. Until the Type A meeting clarifies which path the FDA will accept, we see the full range of outcomes above as live, and we are not updating our investment case or valuation until there is more clarity.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. Michael Friis, 14/07-2026. kl 08:20